Delivery Order SPE2DB20D7059-SPE2DB25FQHS7
Award Date 6/2/25
Potential Completion Date 6/24/25
Potential Value $1K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $13,860.40 by the Defense Logistics Agency (DLA) for the supply of HYPERRAB 300 Unit/ML Vial medication. This firm fixed-price, non-set-aside contract was executed on October 17, 2025, with an ultimate completion date of November 7, 2025. The place of performance is listed as Conshohocken, Pennsylvania, which serves as the company's corporate headquarters. This delivery order is issued under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,744.80 on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL vials (5mL) to support federal medical procurement needs. The award is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 20, 2025, and is funded through the Defense Logistics Agency's Medical Supply Chain division. This contract represents...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside, firm fixed-price delivery order carries a ceiling value of $21,489.60 and is scheduled for completion by September 29, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency issued a delivery order valued at $1,732.55 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed price delivery order, awarded on June 25, 2025, with a completion date of July 17, 2025, represents a non-competitive procurement executed under an existing contract vehicle. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania....
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/mL vials at a ceiling value of $1,039.53, with final completion required by August 18, 2025. This is a firm fixed-price delivery order issued without set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, executed this order...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for HYPERRAB 300 unit/mL vials with a ceiling value of $1,386.04 and an ultimate completion date of May 14, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated as SPE2DX and valued at...
- The Defense Logistics Agency issued a delivery order valued at $3,465.10 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This non-set-aside, firm fixed-price delivery order was awarded on July 23, 2025, with an ultimate completion date of August 13, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. HYPERRAB is a rabies immunoglobulin (human) product used for post-exposure prophylaxis and...
- The Defense Logistics Agency awarded a $3,465.10 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial, a rabies immunoglobulin product used for post-exposure prophylaxis. The award was issued on May 27, 2025, with an ultimate completion date of June 17, 2025, and represents a non-competitive, non-set-aside procurement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,197.65 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with a completion date of September 2, 2025. This is a firm fixed price contract with no set-aside designation, and the pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HYPERRAB is a rabies immunoglobulin used for post-exposure prophylaxis in rabies prevention, representing a critical...
- The Defense Logistics Agency awarded a delivery order valued at $7,163.24 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. The contract, awarded on June 2, 2025, with an ultimate completion date of June 24, 2025, operates under a firm fixed-price structure with no set-aside designation, indicating competitive award. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child...